|
Found 10 result(s) FROM 1963 pages containing the term 'Lyrica'.
Wednesday Mar 03, 2010
Patients Speak Out About the Pain of Fibromyalgia
Sometimes the best way to learn about a disease is to listen to the patients who suffer from it...
Wednesday Apr 08, 2009
FDA Warns Pharma on "Sponsored Links"
FDA has warned 14 pharmaceutical companies about the brief ads that accompany internet search results...
Thursday Feb 26, 2009
Pfizer Stops Work on Esreboxetine for FM
Pfizer has stopped development of esreboxetine, which was in phase II trials for fibromyalgia...
Tuesday Feb 17, 2009
Some TNF Inhibitors Raise Shingles Risk in RA. Time to Vaccinate?
Anti-TNF monoclonal antibody drugs (adalimumab, infliximab) significantly increase herpes zoster risk in RA patients, and vaccination should be considered. Etanercept was not associated with increased herpes zoster risk...
Thursday Oct 23, 2008
New Use of Pregabalin: Preventing Chronic Pain After Knee Replacement
Perioperative pregabalin (Lyrica®) may stave off chronic pain and permit earlier mobility for patients who have total knee replacement…
Tuesday Jun 17, 2008
Cymbalta® Approved for Fibromyalgia
The antidepressant Cymbalta® (duloxetine) has been approved by the US FDA to treat fibromyalgia…
Monday Jan 14, 2008
Drug Approved. Is Disease Real?
As Pfizer markets Lyrica® (pregabalin), the first approved medicine to treat fibromyalgia, doctors debate the legitimacy of the pain syndrome...
Monday Jun 25, 2007
Pfizer's LyricaR Receives FDA Approval for Fibromyalgia in Adults
Pfizer Inc announced that the US FDA approved Lyrica® (pregabalin) capsules CV for the management of fibromyalgia, one of the most common chronic, widespread pain conditions in the US...
Monday Nov 20, 2006
Pregabalin Offers Durable Pain Relief in Fibromyalgia
The anticonvulsant pregabalin may offer extended pain relief to fibromyalgia patients... Crofford LJ, et al. Presented at: ACR 2006 Meeting.
Friday Jan 21, 2005
The Promise and Peril of the Next Generation of COX-2 Inhibitors
CIAOMed continues its series on the impact of the withdrawal of rofecoxib (VioxxR) from the worldwide market. The first installment (CIAOMed.org; November 9, 2004) discussed possible mechanisms of the cardiovascular (CV) risk observed with rofecoxib, and whether they apply to other selective cyclooxygenase-2 (COX-2) inhibitors. The second (CIAOMed.org; December 10, 2004) examined the impact of recent disclosures about COX-2s and CV risk on patient management. This third and final installment focuses on the clues to CV risk profiles of the second-generation COX-2 inhibitors and the role these newer drugs will play if they are approved for marketing in the US& Brune K, Hinz B. Scand J Rheumatol. 2004;33:1-6.
|
